TECHWIRE 30
(CIX: WRAL30)  1,059.57  down arrow-0.48  (-0.05 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: Apple)  102.99  up arrow+0.52  (0.51 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: QUINTILES)  56.55  up arrow+0.05  (0.09 %)  Updated: 06:40 PM EDT, Oct 22 2014
(OP: BASF SE)  87.84  down arrow-1.17  (-1.31 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: BioCryst)  11.70  up arrow+0.33  (2.9 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: BioDelivery)  15.90  down arrow-0.45  (-2.75 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: CEMP)  11.88  down arrow-0.31  (-2.54 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: Cisco Systems)  23.26  down arrow-0.25  (-1.06 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: Cree)  27.28  down arrow-5.87  (-17.71 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: DARA)  0.90  up arrow+0.03  (3.44 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: EMC CORPORATION)  27.37  up arrow+0.17  (0.63 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Extreme Networks)  3.01  down arrow-0.19  (-5.94 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: FB)  78.37  down arrow-0.32  (-0.41 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: GLAXOSMITHKLINE)  44.41  up arrow+0.78  (1.79 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: GOOG)  532.71  up arrow+6.17  (1.17 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: IBM)  161.79  down arrow-1.44  (-0.88 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NY: LH)  101.07  down arrow-0.23  (-0.23 %)  Updated: 06:40 PM EDT, Oct 22 2014
(OP: Lenovo Group)  28.95  down arrow-0.07  (-0.24 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: MRK)  55.51  up arrow+0.38  (0.69 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Microsoft Corp)  44.38  down arrow-0.5  (-1.11 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: NTAP)  39.66  up arrow+0.39  (0.99 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: NOVARTIS AG)  88.20  down arrow-0.41  (-0.46 %)  Updated: 06:40 PM EDT, Oct 22 2014
(OP: Novozymes A/S)  40.92  down arrow-0.17  (-0.4 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: PFIZER)  28.30  up arrow+0.02  (0.07 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Pozen)  8.47  up arrow+0.2  (2.42 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NY: RED HAT)  54.80  down arrow-2.33  (-4.08 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: BBRY)  9.89  down arrow-0.26  (-2.56 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: Salix)  137.61  down arrow-2.94  (-2.09 %)  Updated: 08:10 PM EDT, Oct 22 2014
(NQ: SQI)  15.21  down arrow-0.12  (-0.78 %)  Updated: 08:10 PM EDT, Oct 22 2014

Posts tagged “Intersouth”

Updated July 23, 2012

Premium Lock Despite surge in tech startups, VCs see little chance of a 'bubble'

Venture Update With all the recent programs rolling out to support the launch and growth of new companies, funding remains scarce. If nothing else, lack of cash will keep a damper on entrepreneurs' hopes of flaming beyond control.

Updated July 6, 2012

Premium Lock Biotech firm Biolex, which raised $160M, seeks bankruptcy

The biotechnology firm, backed by Intersouth Partners which is owed some $5 million, has been seeking to development treatments for hepatitis C. Biolex raised $60 million in 2008 in one of the state's biggest venture capital deals. It tried and failed to go public that same year.

Biolex worker eyes lemna plants. Biolex worker eyes lemna plants.

Updated May 1, 2012

Premium Lock Shine on: Durham solar firm Semprius cracks MIT top 10 tech list

The startup company's leading-edge solar technology "could soon make electricity cheaply enough to compete with power plants fueled by coal and natural gas," says the Massachusetts Institute for Technology in its annual "most important technology milestones" list.

Semprius' solar panel technology Semprius' solar panel technology

April 24, 2012

Premium Lock Argos Therapeutics raises $25M after withdrawing IPO

The Durham-based drug development firm lands a new investor as well as more backing from Intersouth and Aurora Funds. The deal follows Argos' recent decision to terminate plans to go public.

Argos process Argos process

March 2, 2012

Premium Lock Biolex sale is an option, CFO tells Triangle Business Journal

Biolex worker eyes lemna plants. The company is looking for drug-development partners but a sale is possible, chief financial officer says.

February 20, 2012

Premium Lock Triangle may draw interest from more life science investors

Venture Briefs Talk can be cheap, of course, and investors who look to Research Triangle Park have been pretty predictable over the years. But some new faces showed up at the CED Life Science Conference - and some familiar ones returned.

Updated February 16, 2012

Premium Lock Argos Therapeutics aims for as much as $79M in IPO

The Durham based venture capital-backed firm estimated an IPO price of between $13 and $15 per share. Some 5.25 million shares will be offered.

Argos process Argos process

February 10, 2012

Premium Lock $40M Aldagen deal is no quick exit for its investors

Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective regenerative medicine therapies for its pipeline. But a payoff remains in the future and depends on drug trial results.

Aldagen's pipeline Aldagen's pipeline

Updated February 9, 2012

Premium Lock Durham stem cell firm Aldagen sold for up to $40M

Regenerative medicine company Cytomedix has acquired the venture-capital backed company in a $16 million stock deal plus millions more in stock options. Aldagen investors include Intersouth and Aurora Funds.

A purified STEM cell A purified STEM cell

Updated February 7, 2012

Premium Lock RTP broadband firm Overture, minus two top execs, launches new look

The global provider of Ethernet related broadband services shortens its name, creates a new logo and revamps its websites. The changes come in the post-Hatteras Network merger, and among the recent moves is the departure of the former Hatteras CEO.

Overture's new logo Overture's new logo

Updated February 4, 2012

Premium Lock CH-based Cempra goes public, raises $50M; shares close up 6 cents

Cempra Pharmaceuticals sells 8.4 million shares at $6 each. The pricing had been expected to be higher.

Cempra Cempra

Updated January 20, 2012

Premium Lock North Carolina venture deals sluggish in '11 but VCs remain upbeat

Deal making totaled only $325 million across 47 deals, the lowest total since 2005 when one excludes the recession year of 2009. Life science deals dominate the fourth quarter.

Transenterix landed $15M in 4Q for its Spider surgical system Transenterix landed $15M in 4Q for its Spider surgical system

Updated January 16, 2012

Premium Lock NC-based Cempra Pharmaceuticals aims to raise $89.7M in public offering

The Chapel Hill-based company wants to sell 6 million shares at a price between $11 and $13 a share. Its underwriters have the right to sell another 900,000 shares.

Cempra Cempra

Updated December 15, 2011

Premium Lock TransEnterix CEO has 'great expectations' for new $15M in funding

Investors in the Research Triangle Park-based medical device company include Aisling Capital, Intersouth Partners, Quaker Partners, SV Life Science Advisers, Synergy Life Science Partners and Parish Capital Advisors.

Transenterix landed $15M in 4Q for its Spider surgical system Transenterix landed $15M in 4Q for its Spider surgical system

November 14, 2011

Premium Lock Intersouth leads $4.5M investment in electronic health records provider

Electronic medical records SimplifyMD, a Georgia-based firm, also names a former McKesson executive as its president. As part of the deal, Intersouth's John Glushnik joins the startup's board.

October 13, 2011

Premium Lock Cempra Pharmaceuticals files plans for $86M IPO

Antibiotics research Cempra does not yet have any Food and Drug Administration-approved products. Its compounds are targeting an antibiotics market that according to Datamonitor totaled $19.6 billion in the United States, Japan and the five major European markets in 2009.

September 20, 2011

Premium Lock Charlotte IT firm raises $6M, adds Red Hat exec to board

Adaptivity raises funds from Intersouth Partners, Noro-Moseley Partners and Intel Capital. The software firm also names a new chief technology officer.

September 20, 2011

Premium Lock Cancer diagnostics startup raises $250,000

Dr. Myla Lai-Goldman GeneCentric Dianostics, which is based in Durham, is led by Hatteras Venture Partners' Myla Lai-Goldman.

September 7, 2011

Premium Lock Frey back in executive saddle as EvoApp CEO

Kip Frey Kip Frey, who left Zenph Sound Innovations last month, is the new CEO at EvoApp.

Updated August 22, 2011

Premium Lock Raleigh 'cloud' startup raises $7M, plans 5-10 new hires

6fusion, which is backed by Intersouth partners, lands a new investor in raising its second investment round.

6fusion's "Cube" concept for managing the "cloud" 6fusion's "Cube" concept for managing the "cloud"

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll